Trial Profile
Azacytidine as post-transplantation prophylactic therapy in patients with high risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.